Drugs / 3,4-Methylenedioxymethamphetamine
3,4-Methylenedioxymethamphetamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01148342 | Feb 2004 → Jul 2012 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,4-Methylenedioxymethamphetamine | “3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a synthetic compound that has shown a steep increase in abuse by young people in recent years.” NCT01148342 ↗ |
| Known as | ecstasy | “3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a synthetic compound that has shown a steep increase in abuse by young people in recent years.” NCT01148342 ↗ |
| Known as | MDMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01148342 ↗ |